Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
BioNTech SE
Scientific Title
Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma